CRSP

CRISPR Therapeutics AG

Price

$54.65

return (12m)

-14.84%

p/e

-10.55

p/bv

2.73

DIVIDEND YIELD

0.00%

CRSP price

CRISPR Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*The amount considers the reinvestment of dividends.

Return on Investment CRSP

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.13%

3 months

14.59%

1 year

-14.84%

2 years

9.94%

5 years

-42.75%

10 years

199.45%

Profitability Comparator

If you had invested

years ago

ago, you would now have:

Fundamentals CRSP

Valuation

P/E

-10.55

Sector -3.10

Industry -3.10

P/BV

2.73

Sector 1.78

Industry 1.78

P/Revenue (PSR)

355.44

Sector 2.00

Industry 2.00

EV/EBITDA

-6.94

Sector -202.91

Industry -202.91

EV/EBIT

-6.65

Sector -40.75

Industry -40.75

P/EBITDA

-11.08

Sector -19.52

Industry -19.52

P/EBIT

-10.62

Sector -64.80

Industry -64.80

P/Total Assets

1.80

Sector 1.06

Industry 1.06

P/Net Current Assets

3.24

Sector -9.29

Industry -9.29

P/Working Capital

2.13

Sector -121.95

Industry -121.95

EPS

-4.67

Sector -1.78

Industry -1.78

BVPS

18.10

Sector 2.01

Industry 2.01

Efficiency

Gross Margin

100.00%

Sector 41.24%

Industry 41.24%

EBITDA Margin

-843.67%

Sector -21,194.51%

Industry -21,194.51%

EBIT Margin

-100.00%

Sector -35.37%

Industry -35.37%

Net Profit Margins

-100.00%

Sector -35.81%

Industry -35.81%

Asset Turnover

0.00

Sector 0.03

Industry 0.03

Profitability

ROE

-25.83%

Sector -57.47%

Industry -57.47%

ROA

-17.02%

Sector -59.48%

Industry -59.48%

ROIC

-136.84%

Sector -1,878.27%

Industry -1,878.27%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

17.85

Sector 2.92

Industry 2.92

Net Debt / EBITDA

4.14

Sector -19.80

Industry -19.80

Net Debt / EBIT

3.97

Sector -4.14

Industry -4.14

Net Debt / Equity

-1.02

Sector -33,113.00

Industry -33,113.00

Gross Debt / Equity

0.34

Sector -0.84

Industry -0.84

Equity/Assets

0.66

Sector 0.46

Industry 0.46

Liabilities/Assets

0.34

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

-57.04%

Sector -

Industry -

5Y Earnings CAGR

0.00%

Sector -

Industry -

Fundamentals CRSP

DRAG THE FRAME TO SEE MORE DATA

Assets	Price ($)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
CRSP CRISPR Therapeutics AG	$54.65	-14.84%	0.00%	-10.55	2.73	-25.83%	-100.00%
PFE Pfizer Inc.	$29.76	31.92%	5.80%	38.97	1.98	5.07%	6.80%
ABBV AbbVie Inc.	$289.32	31.21%	2.40%	79.90	-85.04	-106.44%	9.81%
NVO Novo Nordisk A/S	$38.86	-20.59%	4.76%	9.52	5.05	53.11%	35.32%
MRK Merck & Co. Inc.	$147.57	74.54%	2.34%	113.15	8.55	7.56%	4.77%
AZN AstraZeneca PLC	$174.34	7.84%	1.89%	20.48	5.28	25.77%	16.95%
BMY Bristol-Myers Squibb Company	$60.59	49.75%	4.14%	13.36	5.56	46.70%	18.87%
ZTS Zoetis Inc.	$78.04	-45.30%	2.58%	12.83	10.75	83.77%	27.69%
AMGN Amgen Inc.	$458.51	61.30%	2.25%	27.32	20.44	74.80%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$813.63	25.11%	0.46%	19.24	2.63	13.65%	27.86%
HALO Halozyme Therapeutics Inc.	$130.70	99.85%	0.00%	35.61	102.60	288.13%	24.86%
MCK McKesson Corporation	$968.07	20.90%	0.34%	26.09	-31.01	-118.84%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$539.50	27.72%	0.00%	30.31	6.59	21.76%	35.00%
CAH Cardinal Health Inc.	$249.46	54.69%	0.81%	34.72	-21.85	-62.92%	0.67%
ARGX argenx SE	$896.82	7.23%	0.00%	13.05	3.49	26.71%	25.47%
HRMY Harmony Biosciences Holdings Inc.	$38.53	29.98%	0.00%	11.35	2.06	18.14%	18.88%
BIIB Biogen Inc.	$251.81	68.85%	0.00%	44.37	1.96	4.43%	8.32%
MEDP Medpace Holdings Inc.	$686.35	18.23%	0.00%	38.36	43.45	113.29%	17.67%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

CRSP - Historical Dividends

no dividend paid in the period.

Current Dividend Yield

0.00%

5-year average Dividend Yield

0.00%

Current Payout

—

5-year average Payout

—

ABOUT CRISPR Therapeutics

CRISPR Therapeutics AG

Average Investor10 user rating

4.0 (19 people)

United States

13 years

Founded: 2013

2016

Time since IPO - 10 years

93

Employees

CRISPR Therapeutics AG operates in the healthcare sector, within the biotechnology industry focused on gene-editing and genome-based therapies. The company develops treatments based on CRISPR-Cas9 technology, aimed at modifying DNA to address complex diseases.

Its main areas of activity include:

• Development of gene therapies using CRISPR-Cas9 technology.
• Clinical programs targeting blood disorders and rare diseases.
• Research in oncology, immunotherapy and metabolic conditions.
• Biotechnology platforms for genome-editing innovation.

The company’s portfolio consists of therapies in clinical development, using both ex vivo and in vivo gene-editing approaches to treat conditions such as sickle cell disease and other genetic disorders.

CRISPR Therapeutics operates internationally, with a primary presence in the United States and Europe. Its structure includes research centers, clinical-development teams, regulatory units and partnerships with pharmaceutical companies and academic institutions.

Industry dynamics affecting the company include regulatory frameworks for advanced therapies, competition within the biotechnology sector, high R&D costs, clinical trial outcomes and the growing demand for precision medicine.

Shares of CRISPR Therapeutics AG trade on the Nasdaq under the ticker CRSP.

History and Development

CRISPR Therapeutics was founded in 2013 in Switzerland with the objective of translating CRISPR-Cas9 gene-editing technology into therapeutic applications.

In its early years, the company focused on validating its scientific platform, building intellectual property and establishing a pipeline of potential treatments. Initial progress included preclinical research and the development of early-stage therapeutic programs targeting genetic diseases.

As the company evolved, it expanded its clinical pipeline and formed strategic partnerships with global pharmaceutical companies to support development and commercialization efforts. In 2016, CRISPR Therapeutics completed its initial public offering (IPO) on the Nasdaq, securing funding to advance its clinical programs and expand research capabilities.

In recent years, the company has advanced multiple therapies into clinical trials, particularly in hematology and oncology, while refining its gene-editing technologies.

Additional Information

CRISPR Therapeutics AG (United States) is listed on the Nasdaq and has a market capitalization of $4.76 billion, with shareholders equity totaling $1.75 billion.

The company employs approximately 93 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, CRISPR Therapeutics AG reported $13.39 million in revenue, generating net income of $-451.14 million.

Key financial metrics include a P/E ratio of -10.55, a price-to-book (P/B) ratio of 2.73, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker CRSP.

Market cap

$4.76 billion

Net worth

$1.75 billion

$1,746,551,000.00

Assets

$2.65 billion

$2,650,770,000.00

Total Shares Outstanding

96.51 million

96,514,000

Average Daily Trading Volume

$1.62 million

$1,615,802.00

Sector

Health Care

Industry

Biotechnology

CRSP

CRSP revenue and profits

Financial Results CRSP

DRAG THE FRAME TO SEE MORE DATA

CRSP cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$968.07 20,45% (12M)

P/E

26.09

0.34%

ROE

-118.84%

P/BV

-31.01

CAH - Cardinal Health

$249.46 53,11% (12M)

P/E

34.72

0.81%

ROE

-62.92%

P/BV

-21.85

ABBV - AbbVie

$289.32 32,61% (12M)

P/E

79.90

2.40%

ROE

-106.44%

P/BV

-85.04

MRK - Merck & Co.

$147.57 75,44% (12M)

P/E

113.15

2.34%

ROE

7.56%

P/BV

8.55

AZN - AstraZeneca

$174.34 7,69% (12M)

P/E

20.48

1.89%

ROE

25.77%

P/BV

5.28

PFE - Pfizer

$29.76 33,06% (12M)

P/E

38.97

5.80%

ROE

5.07%

P/BV

1.98

BMY - Bristol-Myers Squibb

$60.59 50,52% (12M)

P/E

13.36

4.14%

ROE

46.70%

P/BV

5.56

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$968.07 20,45% (12 M)

P/L

26.09

0.34%

ROE

-118.84%

P/VP

-31.01

CAH - Cardinal Health

$249.46 53,11% (12 M)

P/L

34.72

0.81%

ROE

-62.92%

P/VP

-21.85

ABBV - AbbVie

$289.32 32,61% (12 M)

P/L

79.90

2.40%

ROE

-106.44%

P/VP

-85.04

MRK - Merck & Co.

$147.57 75,44% (12 M)

P/L

113.15

2.34%

ROE

7.56%

P/VP

8.55

AZN - AstraZeneca

$174.34 7,69% (12 M)

P/L

20.48

1.89%

ROE

25.77%

P/VP

5.28

PFE - Pfizer

$29.76 33,06% (12 M)

P/L

38.97

5.80%

ROE

5.07%

P/VP

1.98

BMY - Bristol-Myers Squibb

$60.59 50,52% (12 M)

P/L

13.36

4.14%

ROE

46.70%

P/VP

5.56

Frequently Asked Questions

What is the price of CRISPR Therapeutics (CRSP) today?

The current price of CRISPR Therapeutics (CRSP) is $54.65. The stock began the year trading around $52.44 and is currently priced at $54.65. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does CRISPR Therapeutics (CRSP) pay dividends?

CRISPR Therapeutics (CRSP) did not pay dividends over the past year.

Is CRISPR Therapeutics (CRSP) a good investment?

CRISPR Therapeutics (CRSP) is currently trading at $54.65 with a P/E ratio of -10.55. This represents a -1,313% premium compared to its historical average P/E. Over the past year, the stock paid $0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was -14.84%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy CRISPR Therapeutics (CRSP) stock?

You can buy CRISPR Therapeutics (CRSP) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol CRSP and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of CRISPR Therapeutics (CRSP) yield today?

Over the past month, CRISPR Therapeutics (CRSP) has returned 0.13% — -14.84% over the past year, and -42.75% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 0.00 per share in dividends, resulting in a dividend yield of 0.00%.

If you were to purchase 100 shares of CRISPR Therapeutics (CRSP) today at the current price of $54.65 your total investment would be $5,465.00.

Based on historical performance, the investment would have grown to approximately:

$4,653.99 after 1 year
$3,128.71 after 5 years
$16,364.94 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

CRSP

CRISPR Therapeutics AG

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment CRSP

Target price created!

Delete target price?

Your Target Price strategy deserves unlimited alerts

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING CRSP WITH OTHER STOCKS

ABOUT CRISPR Therapeutics

CRISPR Therapeutics AG

United States

13 years

2016

93

History and Development

Additional Information

PROFIT X PRICE CRSP

Financial Results CRSP

CRSP cash flow

Asset, Revenue and Profit Growth - CRSP

CRSP balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BMY - Bristol-Myers Squibb

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BMY - Bristol-Myers Squibb

Frequently Asked Questions